|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 16, 2017 ) Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters) , blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 5, 1, 34, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.
Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/diabetic-retinopathy-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834331/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Abzena Plc
Acucela Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Amakem NV
Antisense Therapeutics Ltd
Apollo Endosurgery Inc
BCN Peptides SA
Biomar Microbial Technologies
Charlesson LLC
Coherus BioSciences Inc
Crinetics Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dynamis Therapeutics Inc
EyeGene Inc
Foresee Pharmaceuticals LLC
Fo
rmycon AG
Icon Bioscience Inc
Islet Sciences Inc
Kodiak Sciences Inc
Kowa Company Ltd
Lupin Ltd
M's Science Corp
Mabion SA
Nemus Bioscience Inc
Oculis ehf
Ohr Pharmaceutical Inc
PanOptica Inc
Profarma
Promedior Inc
Regeneron Pharmaceuticals Inc
Ribomic Inc
Strongbridge Biopharma plc
Targazyme Inc
ThromboGenics NV
VESSL Therapeutics Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834331/discount
List of Tables
Number of Products under Development for Diabetic Retinopathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Retinopathy - Pipeline by Abzena Plc, H1 2017
Diabetic Retinopathy - Pipeline by Acucela Inc, H1 2017
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2017
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics Inc, H1 2017
Diabetic Retinopathy - Pipeline by Amakem NV, H1 2017
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
Diabetic Retinopathy - Pipeline by Apollo Endosurgery Inc, H1 2017
Diabetic Retinopathy - Pipeline by BCN Peptides SA, H1 2017
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2017
Diabetic Retinopathy - Pipeline by Charlesson LLC, H1 2017
Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H1 2017
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H1 2017
Diabetic Retinopathy - Pipeline by EyeGene Inc, H1 2017
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Diabetic Retinopathy - Pipeline by Formycon AG, H1 2017
Diabetic Retinopathy - Pipeline by Icon Bioscience Inc, H1 2017
Diabetic Retinopathy - Pipeline by Islet Sciences Inc, H1 2017
Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H1 2017
Diabetic Retinopathy - Pipeline by Kowa Company Ltd, H1 2017
Diabetic Retinopathy - Pipeline by Lupin Ltd, H1 2017
Diabetic Retinopathy - Pipeline by M's Science Corp, H1 2017
Diabetic Retinopathy - Pipeline by Mabion SA, H1 2017
Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H1 2017
Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2017
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H1 2017
Diabetic Retinopathy - Pipeline by PanOptica Inc, H1 2017
Diabetic Retinopathy - Pipeline by Profarma, H1 2017
Diabetic Retinopathy - Pipeline by Promedior Inc, H1 2017
Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Diabetic Retinopathy - Pipeline by Ribomic Inc, H1 2017
Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H1 2017
Diabetic Retinopathy - Pipeline by Targazyme Inc, H1 2017
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2017
Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H1 2017
Diabetic Retinopathy - Dormant Projects, H1 2017
Diabetic Retinopathy - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Diabetic Retinopathy - Dormant Projects, H1 2017 (Contd..2) , H1 2017
Diabetic Retinopathy - Dormant Projects, H1 2017 (Contd..3) , H1 2017
Diabetic Retinopathy - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834331/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
